Business Context and Reporting Period
This Form 8-K is filed by OncoGenex Pharmaceuticals, Inc. (noted as "ACHIEVE LIFE SCIENCES, INC." in metadata, but identified as OncoGenex in the filing text) on March 8, 2010. The report discloses the issuance of a press release regarding financial results for the fourth quarter and full year ended December 31, 2009.
Key Financial Metrics
The filing text serves as a notification of results and incorporates the press release by reference but does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity within the body of this 8-K document. Investors must refer to the attached Exhibit 99.1 (Press Release) for these figures.
Material Changes
No specific material changes or comparative financial data are detailed in this filing text. The document solely announces the availability of the Q4 and full-year 2009 results.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It strictly references the attached press release for the announcement of results.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in the attached Exhibit 99.1 Press Release, as they are not listed in this summary.
- Confirm the company name discrepancy between the metadata ("ACHIEVE LIFE SCIENCES, INC.") and the filing text ("ONCOGENEX PHARMACEUTICALS, INC.").
- Review the press release for any operational updates or clinical trial milestones associated with the 2009 results.